伴环形铁粒幼细胞的骨髓增生异常综合征及MDS/MPN伴RS和血小板增多症:2021年诊断、危险分层和管理更新
该综述更新了伴环形铁粒幼细胞(RS)的两种髓系肿瘤:MDS-RS和MDS/MPN-RS-T的诊断标准、分子特征、危险分层及治疗。MDS-RS为低危MDS,SF3B1突变率≥80%;MDS/MPN-RS-T具有MDS-RS-SLD特征伴血小板≥450×10^9/L。两者贫血和铁过载管理相似,luspatercept已获批用于贫血治疗,阿司匹林可用于MDS/MPN-RS-T。
要点
- MDS-RS诊断需≥15%骨髓RS(伴SF3B1突变时≥5%),原始细胞<5%骨髓、<1%外周血。
- MDS/MPN-RS-T诊断需MDS-RS-SLD特征、血小板≥450×10^9/L及大而不典型巨核细胞。
- Luspatercept获批用于MDS-RS和MDS/MPN-RS-T贫血;阿司匹林可用于MDS/MPN-RS-T,尤其JAK2V617F阳性者。
核心结论
- MDS-RS和MDS/MPN-RS-T是两种由RS定义的髓系肿瘤,均以贫血和铁过载为并发症,白血病转化风险低。
- MDS/MPN-RS-T预后优于MDS-RS-SLD但劣于ET。
研究设计与样本
- 综述,检索范围未在原文摘要中报告。
主要发现
- SF3B1突变见于≥80%的MDS-RS-SLD和MDS/MPN-RS-T患者,与骨髓RS强相关。
- MDS/MPN-RS-T患者中JAK2V617F占50%,还可见DNMT3A、TET2和ASXL1突变。
- 两种疾病细胞遗传学异常均不常见。
- 多数MDS-RS-SLD患者按修订IPSS归为较低危组。
关键数值与推荐
- MDS-RS诊断:单系或多系病态造血,骨髓原始细胞<5%,外周血原始细胞<1%,骨髓RS≥15%(伴SF3B1突变时≥5%)。
- MDS/MPN-RS-T诊断:MDS-RS-SLD特征,血小板计数≥450×10^9/L,大而不典型巨核细胞。
临床怎么用
- 贫血和铁过载按低危MDS和MPN原则管理。
- Luspatercept(首创红细胞成熟剂)已获批用于MDS-RS和MDS/MPN-RS-T贫血。
- MDS/MPN-RS-T可考虑阿司匹林,尤其JAK2V617F阳性者;降血小板药物的价值尚未确定。
局限性
- 原文摘要未报告综述的检索范围及纳入研究数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include myelodysplastic syndromes with RS (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T). DIAGNOSIS: MDS-RS is a lower risk MDS, with single or multilineage dysplasia (MDS-RS-SLD/MLD), <5% bone marrow (BM) blasts, <1% peripheral blood blasts and ≥15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN-RS-T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS-RS-SLD, along with a platelet count ≥450 × 109 /L and large atypical megakaryocytes. MUTATIONS AND KARYOTYPE: Mutations in SF3B1 are seen in ≥80% of patients with MDS-RS-SLD and MDS/MPN-RS-T, and strongly correlate with the presence of BM RS; MDS/MPN-RS-T patients also demonstrate JAK2V617F (50%), DNMT3A, TET2 and ASXL1 mutations. Cytogenetic abnormalities are uncommon in both. RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower risk groups by the revised-IPSS. Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythemia (MPN). Both diseases are associated with a low risk of leukemic transformation. TREATMENT: Anemia and iron overload are complications seen in both and are managed similar to lower risk MDS and MPN. Luspatercept, a first-in-class erythroid maturation agent is now approved for the management of anemia in patients with MDS-RS and MDS/MPN-RS-T. Aspirin therapy is reasonable in MDS/MPN-RS-T, especially in the presence of JAK2V617F, but the value of platelet-lowering drugs remains to be defined.
引用
- Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". Am J Hematol. 2021. PMID: 33428785. doi:10.1002/ajh.26090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。